Back to News
Market Impact: 0.25

Warren Buffett Detailed Fundamental Analysis

ACNNDAQ
Company FundamentalsAnalyst InsightsCorporate EarningsCapital Returns (Dividends / Buybacks)Technology & Innovation
Warren Buffett Detailed Fundamental Analysis

Accenture (ACN) received a 77% rating from Validea's Warren Buffett-inspired Patient Investor model, placing it just below the 80% threshold for 'some interest.' While ACN demonstrates strong fundamentals, including predictable earnings, low debt, and robust returns on equity and total capital, it notably failed the 'Initial Rate of Return' criterion. This assessment suggests ACN aligns with many Buffett-style quality metrics but does not present a strong valuation opportunity according to this specific investment strategy.

Analysis

According to Validea's Patient Investor model, which is based on Warren Buffett's investment strategy, Accenture PLC (ACN) exhibits strong fundamental quality but falls short on valuation. With a score of 77%, just below the 80% threshold for interest, the company passes key tests for earnings predictability, low debt service, high return on equity, and robust return on total capital. These factors highlight ACN as a durable, highly profitable, and financially sound enterprise consistent with a high-quality, long-term holding. However, the analysis reveals a critical weakness: the stock fails the 'Initial Rate of Return' test, indicating that its current market price may not provide a sufficient margin of safety or an attractive entry point for value-focused investors. The 'NEUTRAL' rating on share repurchases suggests capital return activities are adequate but not a strong positive driver for the model. In essence, the report characterizes ACN as a high-quality company trading at a potentially full valuation.

AllMind AI Terminal

AI-powered research, real-time alerts, and portfolio analytics for institutional investors.

Request a Demo